First published 10/3/2026, 12:34:15 AM · Last updated 10/3/2026, 12:34:15 AM

MA03.01 Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC

A journal article reports that ultrasensitive MRD improves detection in resectable Stage I non–small cell lung cancer (NSCLC). Publisher listed as Elsevier BV with publication date 2025-10-01.

Illustrative image: Tumor cells can either be eliminated by the immune system or escape detection. During the elimination phase, immune effector cells such as natural killer cells, with the help of dendritic and CD4+ T-cells, are able to recognize and eliminate tumor cells (left). As a result of heterogeneity, however, tumor cells which are less immunogenic are able to escape immunosurveillance (right). — Frontiers in Oncology/Wikimedia Commons, CC BY 3.0

Categories: science-and-space, public-health, positive-progress

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 4/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 3/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

MA03.01 Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC

Generated scores

Why it matters

Sources